Treatment strategies of recurrent hepatitis C after liver transplantation based on IL28B singlencleotide polymorphism.

2013 Fiscal Year Final Research Report

• Project/Area Number: 23390328
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Hokkaido University
• Principal Investigator: TAKETOMI Akinobu 北海道大学, 医学(系)研究科(研究院), 教授 (70363364)
• Co-Investigator(Kenkyū-buntansha): MAEHARA Yoshihiko 九州大学, 大学院・医学研究科, 教授 (80165662) ; SHIRABE Ken 九州大学, 大学院・医学研究科, 准教授 (70264025) ; MATSUURA Yoshiharu 大阪大学, 微生物病研究所, 教授 (50157252) ; FUKUHARA Takasuke 大阪大学, 微生物病研究所, 助教 (70598739) ; YOSHIZUMI Tomoharu 九州大学, 大学院・医学研究科, 准教授 (80363373) ; UCHIYAMA Hideaki 九州大学, 大学病院, 特任助教 (70380425)
• Project Period (FY): 2011-04-01 – 2014-03-31
• Keywords: 肝移植 / C型肝炎 / 遺伝子多型 / SVR

Research Abstract

A nationwide survey of living donor liver transplantation (LDLT) for hepatitis C virus-positive recipients was performed in Japan. Of 514 recipients collected in the study, 361 patients underwent antiviral treatment after liver transplantation. VR rate was 64.1%, and SVR rate was 38.3%. The 5-yr and 10-yr cumulative patient survival with SVR (94.1% and 83.0%) were significantly superior than those without SVR (79.7% and 60.8%). Presence of the major allele (TT) in both the recipient and the donor corresponded to SVR of 58.2%. Presence of the minor allele (TG or GG) in either the recipient or the donor corresponded to SVR of 15.7%, 16.7% and 28.5%. Multivariate analysis revealed that genotype of IL28B polymorphisms in either the recipient or donor was an independent factor for achieving SVR. In conclusion, our study demonstrated that both donor and recipient IL28B genotype were strongly associated with graft survival and response to IFN/RBV therapy for LDLT recipients.

Research Products

• [Journal Article] Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant (2014)
  • Author(s): Konishi H, Motomura T, Matsumoto Y, Harimoto N, Ikegami T, Yoshizumi T, Soejima Y, Shirabe K, Fukuhara T, Maehara Y
  • Journal Title: J Viral Hepat Volume: 21(6) Pages: 397-404
  • DOI: 10.1111/jvh.12154
  • Peer Reviewed
• [Journal Article] Frequent plasma cell hepatitis during telaprevir-based triple therapy for hepatitis C after liver transplantation (2014)
  • Author(s): Ikegami T, Yoshizumi T, Shirabe K, Maehara Y
  • Journal Title: J Hepatol Volume: 60(4) Pages: 894-6
  • DOI: 10.1016/j.jhep.2013.10.037
  • Peer Reviewed
• [Journal Article] Outcomes of living donor liver transplantation for HCV-positive recipients in Japan : results of a nationwide survey (2014)
  • Author(s): Akamatsu N, Sugawara Y, Kokudo N, Eguchi S, Fujiwara T, Ohdan H, Nagano H, Taketomi A, Kitagawa Y, Shimada M, Ku Y, Yanaga K, Shirabe K, Ikegami T, Mizokami M, Takeuchi M, Maehara Y
  • Journal Title: Transpl Int Volume: 31
  • DOI: 10.1111/tri.12329
  • Peer Reviewed
• [Journal Article] Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C (2013)
  • Author(s): Konishi H, Shirabe K, Yoshiya S, Ikeda T, Ikegami T, Yoshizumi T, Ikawa-Yoshida A, Motomura T, Fukuhara T, Maehara Y
  • Journal Title: Hepatol Res Volume: 43(11) Pages: 1139-47
  • DOI: 10.1111/hepr.12070
  • Peer Reviewed
• [Journal Article] Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation (2013)
  • Author(s): Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, Shimoda S, Soejima Y, Motomura T, Fukuhara T, Maehara Y
  • Journal Title: Transplantation Volume: 95(6) Pages: e38-42
  • DOI: 10.1097/TP.0b013e318283a82e
  • Peer Reviewed
• [Journal Article] Reliability and validity of a new living liver donor quality of life scale (2013)
  • Author(s): Morooka Y, Umeshita K, Taketomi A, Shirabe K, Maehara Y, Yamamoto M, Shimamura T, Oshita A, Kanno K, Ohdan H, Kawagishi N, Satomi S, Ogawa K, Hagiwara K, Nagano H
  • Journal Title: Surg Today Volume: 43(7) Pages: 732-40
  • Peer Reviewed
• [Journal Article] Primary graft dysfunction after living donor liver transplantation is characterized by delayed functional hyperbilirubinemia (2012)
  • Author(s): Ikegami T, Shirabe K, Yoshizumi T, Aishima S, Taketomi A, Soejima Y, Uchiyama H, Kayashima H, Toshima T, Maehara Y
  • Journal Title: Am J Transplant Volume: 12(7) Pages: 1886-97
  • Peer Reviewed
• [Journal Article] Impact of Human T-Cell Leukemia Virus Type 1 in Living Donor Liver Transplantation (2012)
  • Author(s): Yoshizumi T, Shirabe K, Ikegami T, Kayashima H, Yamashita N, Morita K, Masuda T, Hashimoto N, Taketomi A, Soejima Y, Maehara Y
  • Journal Title: Am J Transplant Volume: 12(6) Pages: 1479-85
  • Peer Reviewed
• [Journal Article] Left lobe living donor liver transplantation in adults (2012)
  • Author(s): Soejima Y, Shirabe K, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Ninomiya M, Harada N, Ijichi H, Maehara Y
  • Journal Title: Am J Transplant Volume: 12(7) Pages: 1877-85
  • Peer Reviewed
• [Journal Article] Risk factors that increase mortality after living donor liver transplantation (2012)
  • Author(s): Yoshizumi T, Shirabe K, Taketomi A, Uchiyama H, Harada N, Ijichi H, Yoshimatsu M, Ikegami T, Soejima Y, Maehara Y
  • Journal Title: Transplantation Volume: 93(1) Pages: 93-8
  • Peer Reviewed
• [Journal Article] Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype (2012)
  • Author(s): Motomura T, Koga E, Taketomi A, Fukuhara T, Mano Y, Muto J, Konishi H, Toshima T, Uchiyama H, Yoshizumi T, Shirabe K, Maehara Y
  • Journal Title: Hepatol Res Volume: 42(3) Pages: 288-95
  • Peer Reviewed